Drug Trial Radar · NCT07342491
Dasatinib for HIV-1 Reservoir Reduction
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
May 8, 2026
Primary completion
Apr 9, 2027
Study completion Sep 24, 2027
Sponsor
- Sponsor type
- NIH
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or older who have been on ART for at least 48 months and have had a suppressed HIV-1 viral load for at least 36 months may be able to join. People will be randomly assigned to take dasatinib 100 mg by mouth once a day or a look-alike substance with no drug, called a placebo, for 12 weeks. Neither participants nor researchers will know who gets which (double-blind). The study team will do regular health checks and blood tests to track safety, tolerability, the HIV reservoir, and changes in immune cells. The study lasts 36 weeks total: 12 weeks of treatment and 24 weeks of follow-up, with clinic visits and possible phone calls. Fourteen people will take part; eight will get dasatinib and six will get placebo. Dasatinib may lower the HIV reservoir, but this is not guaranteed. All medicines can cause side effects, called adverse events (AE). The study team will watch closely and provide medical support. Joining is your choice, and you can leave at any time. If you leave, the team will talk with you about next steps for your care.
Conditions
- HIV Infections
Interventions
DasatinibDrug
will be administered as one 100 mg capsule (over-encapsulated tablet) orally once daily for 12 weeks
PlaceboOther
Placebo for dasatinib will be administered as one placebo capsule (over-encapsulated tablet) orally once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in intact HIV-1 reservoir sizeTime frame: Baseline and week 12
- Number of Study treatment-related adverse eventsTime frame: From first dose through week 36
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Northwestern University CRS (Site # 2701)
Chicago, Illinois · Recruiting
2501, Case Clinical Research Site
Cleveland, Ohio · Recruiting
1401, University of Washington Positive Research CRS
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.